In conclusion, although our results should be confirmed by a larger cohort and prospective studies, our results suggest that ERα and galectin-3 are markers of aggressiveness and prognosis in PRL-secreting pituitary tumors and may be tested for identifying aggressive forms of the disease, in the field of personalized therapy, with a multidisciplinary approach. This evidence concerns the gene ESR1 and pituitary tumor.